The inflammation-based modified Glasgow Prognostic Score in patients with vulvar cancer

ObjectivesTo evaluate the prognostic potential of the modified Glasgow Prognostic Score (mGPS), known to reflect the degree of tumor-associated inflammation and cachexia, in patients with vulvar cancer.Study designWe included 93 consecutive patients with vulvar cancer into our study. As previously published, the pre-therapeutic mGPS was calculated as follows: patients with elevated C-reactive protein (CRP) serum levels (>10 mg/L) and hypoalbuminaemia (<35 g/L) were allocated a score of 2, patients with elevated CRP serum levels without hypoalbuminaemia were allocated a score of 1, patients with normal CRP serum levels with or without hypoalbuminaemia were allocated a score of 0. The mGPS was correlated with clinico-pathological parameters. The association between mGPS and prognosis was evaluated by univariate and multivariate survival analysis.ResultsMean (SD) pretreatment CRP and albumin serum levels were 9.5 (9.6) mg/L and 41.4 (5.3) g/L, respectively. mGPS was associated with tumor stage (p = 0.01), but not with lymph node involvement (p = 0.4), histological grade (p = 0.8), and patients’ age (p = 0.7). In univariate analyses, mGPS (p = 0.006, p = 0.001), tumor stage (p < 0.001, p < 0.001), lymph node involvement (p < 0.001, p < 0.001), and patients’ age (p = 0.04, p = 0.007), but not histological grade (p = 0.1, p = 0.3) and year of surgery (1995–2001 vs. 2002–2008, p = 0.7, p = 0.3) were associated with disease-free and overall survival, respectively. In a multivariate analysis, tumor stage (p = 0.01, p = 0.02) and lymph node involvement (p < 0.001, p = 0.001), but not mGPS (p = 0.7, p = 0.8), patients’ age (p = 0.6, p = 0.4), histological grade (p = 0.2, p = 0.1), and year of surgery (p = 0.4, p = 0.8) were associated with disease-free and overall survival, respectively.ConclusionsDespite being associated with prognosis in a univariate analysis, mGPS cannot be used as an independent inflammation-based predictor for survival in patients with vulvar cancer.